94413-69-1

Basic information

• Product Name: 2-Aminomethyl-isonicotinic acid methyl ester
• Synonyms: 2-Aminomethyl-isonicotinic acid methyl ester;methyl 2-(aminomethyl)pyridine-4-carboxylate hydrochloride;methyl 2-(aminomethyl)isonicotinate HCl;Methyl 2-(aminomethyl)isonicotinate hydrochloride;Methyl 2-(aMinoMethyl)pyridine-4-carboxylate dihydrochloride;methyl 2-(aminomethyl)pyridine-4-carboxylate
• CAS NO: 94413-69-1
• Molecular Formula: C₈H₁₀N₂O₂
• Molecular Weight: 202.64
• Product Categories: CHIRAL CHEMICALS
• Mol File: 94413-69-1.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 286°C at 760 mmHg
• Flash Point: 126.8°C
• Appearance: /
• Density: 1.182g/cm³
• Vapor Pressure: 0.00271mmHg at 25°C
• Refractive Index: 1.547
• Storage Temp.: 2-8°C
• PKA: 8.43±0.39(Predicted)
• CAS DataBase Reference: 2-Aminomethyl-isonicotinic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Aminomethyl-isonicotinic acid methyl ester(94413-69-1)
• EPA Substance Registry System: 2-Aminomethyl-isonicotinic acid methyl ester(94413-69-1)

Safety Data

• Hazardous Substances Data: 94413-69-1(Hazardous Substances Data)

Usage

Uses

Methyl 2-(aminomethyl)pyridine-4-carboxylate, HCl

InChI:InChI=1/C8H10N2O2/c1-12-8(11)6-2-3-10-7(4-6)5-9/h2-4H,5,9H2,1H3

Upstream product

• 66572-56-3 2-bromoisonicotinic acid 
• 94413-64-6 2-Cyano-4-carbomethoxypyridine 

Relevant articles and documents

BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE

Described herein are bifunctional degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment of conditions, diseases, and disorders mediated by various target proteins.

POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE

The invention provides compositions and methods for the treatment or prevention of pain. The invention provides constructs whereby hydrolysis of the construct by a specified gastrointestinal enzyme directly, or indirectly, releases an opioid when taken orally as prescribed. The gastrointestinal enzyme mediated release of opioid from constructs of the invention is designed to be attenuated in vivo via a saturation or inhibition mechanism when overdoses are ingested. The invention further provides constructs that are highly resistant to oral overdose, chemical tampering, and abuse via non-oral routes of administration.

Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease

The invention provides compounds of Formula I: 1These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat conditions or diseases in which α7 is known to be involved.